Fludarabine, idarubicin, and cytarabine regimen together with TKI followed by haploidentical hematopoietic stem cell transplantation, a success for relapsed Ph+ acute lymphoblastic leukemia

Wei Sang; Ying Wang; Cong Zhang; Dongmei Yan; Mingshan Niu; Chun Yang; Xia Liu; Cai Sun; Zhe Zhang; Thomas P Loughran Jr; Kailin Xu

doi:10.1002/ccr3.438

Fludarabine, idarubicin, and cytarabine regimen together with TKI followed by haploidentical hematopoietic stem cell transplantation, a success for relapsed Ph+ acute lymphoblastic leukemia

Clin Case Rep. 2016 Mar 4;4(4):390-5. doi: 10.1002/ccr3.438. eCollection 2016 Apr.

Authors

Wei Sang¹, Ying Wang¹, Cong Zhang¹, Dongmei Yan¹, Mingshan Niu¹, Chun Yang², Xia Liu³, Cai Sun¹, Zhe Zhang¹, Thomas P Loughran Jr⁴, Kailin Xu¹

Affiliations

¹ Department of Hematology Affiliated Hospital of Xuzhou Medical College Xuzhou China.
² Department of Radiology Affiliated Hospital of Xuzhou Medical College Xuzhou China.
³ Department of Pathology Affiliated Hospital of Xuzhou Medical College Xuzhou China.
⁴ Department of Medicine University of Virginia Cancer Center Charlottesville Virginia.

Abstract

In this report, a case of relapsed Ph+ ALL was remedied by reinduction, and consolidation regimen of TKI and Flu+ Ara-C+ IDA (FLAI) combination, followed by haploidentical SCT. Results suggest that FLAI together with TKI and subsequently with haploidentical SCT could be applied for relapsed Ph+ ALL.

Keywords: Allogeneic hematopoietic stem cell transplantation; Ph+ acute lymphoblastic leukemia; T cells; graft‐versus‐host disease.

Publication types

Case Reports